|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Carmot Therapeutics
| | | Year Established: | 2008 | Main Contact: | Elena Viboch, Director of Business Development & Operations | | Other Contacts: | Daniel Erlanson, Ph.D., Co-founder & VP of Chemistry Stig K. Hansen, Ph.D., Co-Founer & CEO
| | Company Description | Chemotype Evolution, to identify superior therapeutics for human diseases. The technology provides rapid access to novel, target-relevant chemical diversity, thereby addressing important unmet chemical needs. Moreover, Chemotype Evolution can identify small molecules with functional properties of much larger peptides, a challenging goal in drug discovery. Carmot is applying Chemotype Evolution to identify leads for difficult protein-protein interactions and GPCR targets in metabolic disease, oncology, and inflammation. Carmot is further exploiting Chemotype Evolution by working with industry partners on targets of mutual interest.
Chemotype Evolution is a patent pending technology that was invented by Drs. Stig K. Hansen and Daniel A. Erlanson while they were working at Sunesis Pharmaceuticals. Carmot Therapeutics was founded by Drs. Hansen and Erlanson with the goal of commercializing and further developing the technology. Carmot has licensed the technology and fragment libraries from Sunesis. | |
|
|
|
|
|